4.6 Article

Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial

期刊

CANCER BIOLOGY & MEDICINE
卷 19, 期 7, 页码 1100-1108

出版社

CHINA ANTI-CANCER ASSOC
DOI: 10.20892/j.issn.2095-3941.2022.0085

关键词

Breast cancer; sentinel lymph node biopsy; F-18-fluorodeoxyglucose; LymphPET; negative predictive value

资金

  1. Ministry of Education Innovation Team [IRT1223]
  2. Shanghai Health System Joint Project of Key Disease [2013ZYJB0302]

向作者/读者索取更多资源

This study evaluated the negative predictive value (NPV) of F-18-FDG dedicated lymph node positron emission tomography (LymphPET) in breast cancer patients. The results showed that LymphPET has a high NPV (>90%) for detecting macrometastasis of lymph nodes. Therefore, LymphPET can be used to screen patients and potentially avoid unnecessary sentinel lymph node biopsy (SLNB).
Objective: Sentinel lymph node biopsy (SLNB) is currently the standard of care in clinically node negative (cN0) breast cancer. The present study aimed to evaluate the negative predictive value (NPV) of F-18-FDG dedicated lymph node positron emission tomography (LymphPET) in cN0 patients. Methods: This was a prospective phase II trial divided into 2 stages (NCT04072653). In the first stage, cN0 patients underwent axillary LymphPET followed by SLNB. In the second stage, SLNB was omitted in patients with a negative preoperative axillary assessment after integration of LymphPET. Here, we report the results of the first stage. The primary outcome was the NPV of LymphPET to detect macrometastasis of lymph nodes (LN-macro). Results: A total of 189 patients with invasive breast cancer underwent LymphPET followed by surgery with definitive pathological reports. Forty patients had LN-macro, and 16 patients had only lymph node micrometastasis. Of the 131 patients with a negative LymphPET result, 16 patients had LN-macro, and the NPV was 87.8%. After combined axillary imaging evaluation with ultrasound and LymphPET, 100 patients were found to be both LymphPET and ultrasound negative, 9 patients had LN-macro, and the NPV was 91%. Conclusions: LymphPET can be used to screen patients to potentially avoid SLNB, with an NPV > 90%. The second stage of the SOAPET trial is ongoing to confirm the safety of omission of SLNB according to preoperational axillary evaluation integrating LymphPET.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据